As of Sep 30
| +0.05 / +4.55%|
The 3 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 3.00, with a high estimate of 7.00 and a low estimate of 1.00. The median estimate represents a +160.87% increase from the last price of 1.15.
The current consensus among 3 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.